05:46 AM EDT, 05/18/2026 (MT Newswires) -- BofA Global Research kept its buy rating on Genmab (GMAB.CO), with a price objective of 2,500 Danish kroner, highlighting three important catalysts in 2026 that offer potential upside to its forecasts.

The research firm identified the Epkinly first-line diffuse large B-cell lymphoma data expected in 2026 as one of the major positive catalysts for the Danish biotechnology company, according to a May 15 note. The other two are the data for Rina-S second-line platinum-resistant ovarian cancer and petosemtamab head and neck phase 3 interims expected in the second half.

"We refresh our overview of the three key catalysts coming in the 9 months with a focus on dynamics for each read, alongside our views on current debates. We see a particularly attractive entry point with upcoming catalysts risk-reward positive and we remain bullish chance of data success and unconcerned by recent debates (Epkinly interim and Peto upsizing),"analysts wrote.

"Overall we are bullish the catalysts seeing each of the three as $2bn peak sales opps in attractive markets - with strong precedent datasets, and KOL feedback supportive. Positive data can derisk GMAB's path to offset its Darzalex LOE (28-30E). We estimate the three key catalysts offer a potential c40% 35E EPS upside."